Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05707286 · ClinicalTrials.gov registry record
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 98
- Enrollment target
NCT05707286 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 98 participants.
The verdict
NCT05707286 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and negative clinical outcomes during checkpoint inhibitor therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2025-01-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05707286
The ClinicalTrials.gov registry entry for NCT05707286 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05707286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05707286 about?
NCT05707286 is a clinical study titled "Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy". This research aims to identify clinical strategies to manage adverse events during immune checkpoint inhibitor therapy by (1) determining the impact of checkpoint inhibitors on metabolism through major CYP enzymes and (2) identifying associations between pro-inflammatory cytokine concentrations and ...
What is the current status of trial NCT05707286?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2023-09-07. Estimated completion is 2025-01-20.
Who is sponsoring clinical trial NCT05707286?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.